



"dil" Complex, S. V. Road, Majiwada, Thane(W)- 400 607, INDIA.

Tel. : +91-22-5598 0888

: +91-22-5598 0800

Fax : +91-22-5598 0999

Email : contact@dil.net

www.dil.net

DIL Limited

Unaudited financial results for the quarter ended June 30, 2008.

(Rupees in Lakhs)

Sr. No.	Particulars	Unaudited Quarter ended		Audited Year Ended	Consolidated		
		June 30,		March 31,	June 30,		Audited Year Ended
		2008	2007	2008	2008	2007	2008
		(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)
1	Gross sales & other operating income	297.79	185.14	887.00	1,298.65	1,146.07	5,397.22
	Less: Excise duty	-	-	-	36.58	39.07	130.09
	Net sales & other operating income	297.79	185.14	887.00	1,262.07	1,107.00	5,267.13
2	Other income	9.65	59.62	93.10	38.56	69.25	153.44
3	Expenditure						
	a) (Increase)/decrease in stock-in-trade	-	-	-	(91.90)	45.52	(123.03)
	b) Consumption of raw-materials	-	-	-	288.41	244.98	1,289.08
	c) Cost of production - Motion Film	-	-	30.00	-	-	30.00
	d) Processing charges	-	-	-	30.51	34.63	254.08
	e) Staff cost	67.17	41.21	205.39	420.33	257.91	1,217.71
	f) Exchange loss (net)	-	0.47	0.98	-	19.87	-
	g) Excise duty	-	-	-	9.27	(12.25)	26.09
	h) Sales promotion expenses	1.24	1.69	8.42	5.34	5.34	19.37
	i) Legal & professional expenses	11.23	16.63	63.19	59.98	43.66	192.34
	j) Repairs & maintenance	23.14	11.86	95.59	35.58	19.35	159.26
	k) Brokerage	3.68	-	16.39	3.68	-	16.39
	l) Provision for doubtful debts	-	-	-	-	-	25.61
	m) Depreciation	23.98	22.97	128.16	100.35	82.73	400.44
	n) Other expenditure	42.74	37.29	159.39	308.47	232.68	1,104.54
	Total expenditure (a to n)	173.18	132.12	707.51	1,170.02	974.42	4,611.88
4	Deferred revenue expenditure written off	-	-	-	0.06	0.01	0.06
5	Interest	0.47	0.38	1.42	31.77	6.23	77.75
6	Profit before tax and exceptional item	133.79	112.26	271.17	98.78	195.59	730.88
7	Exceptional item - depreciation written back	158.12	-	-	337.10	-	-
8	Profit before tax	291.91	112.26	271.17	435.88	195.59	730.88
9	Tax expense (including Deferred tax and Fringe benefits tax)	73.94	23.89	32.65	106.39	35.69	107.46
10	Provision for tax in respect of earlier years written back	-	-	21.22	-	-	55.22
11	Share of minority interest	-	-	-	57.61	(1.55)	21.60
12	Net profit after tax	217.97	88.37	259.74	387.10	158.35	700.24
13	Paid-up equity share capital (Face value Rs 10/- per share)	229.32	229.32	229.32	229.32	229.32	229.32
14	Reserves excluding revaluation reserves	-	-	6,796.46	-	-	7,523.57
15	Basic and diluted EPS (Rs/Share)	9.51	3.85	11.33	16.88	6.91	30.54
16	Public shareholding						
	- Number of shares	926,905	926,905	926,905	926,905	926,905	926,905
	- Percentage to shareholding	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%

* Refer note No. 2

@ For the Quarter not annualised

2

Segment-wise Revenue, Results and Capital employed under Clause 41 of the Listing agreement

Particulars	Unaudited Quarter ended		Audited	Consolidated		
	June 30,		Year ended	Unaudited Quarter ended		Audited
	2008		March 31,	June 30,		Year Ended
	2008	2007	2008	2008	2007	March 31,
	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	2008
Segment revenue						
- Bulk drugs/chemicals				594.80	578.82	3,190.91
- Research & development				460.07	381.86	1,439.16
- Treasury & others	307.44	244.76	943.20	313.91	247.13	975.25
- Entertainment	-	-	36.90	-	-	36.90
Total	307.44	244.76	980.10	1,368.78	1,207.81	5,642.22
Less : Inter-segment revenue	-	-	-	68.15	31.56	221.65
Net sales/income from operation	307.44	244.76	980.10	1,300.63	1,176.25	5,420.57
Segment results {profit/(loss) before interest and tax}						
- Bulk drugs/chemicals				42.22	49.91	529.72
- Research & development				(42.50)	47.21	23.64
- Treasury & others	145.51	126.99	335.07	142.46	119.16	345.50
- Entertainment	(11.25)	(14.35)	(62.48)	(11.25)	(14.35)	(62.48)
	134.26	112.64	272.59	130.93	201.93	836.38
Less : Interest expense	0.47	0.38	1.42	31.77	6.23	77.75
	133.79	112.26	271.17	99.16	195.70	758.63
Less: Inter-segment results	-	-	-	0.38	0.11	27.75
Total profit before tax & exceptional items	133.79	112.26	271.17	98.78	195.59	730.88
Exceptional item - depreciation written back	158.12	-	-	337.10	-	-
Profit before tax	291.91	112.26	271.17	435.88	195.59	730.88
Capital employed (Segment assets)						
Less Segment liabilities)						
- Bulk Drugs/chemicals				2,816.35	2,366.38	2,742.36
- Research & development				1,764.74	816.14	1,532.59
- Treasury & others	7,050.97	7,111.79	6,837.51	3,731.83	4,258.34	3,356.22
- Entertainment	6.64	6.38	1.03	6.64	6.38	1.03
Total Capital employed	7,057.61	7,118.17	6,838.54	8,319.56	7,447.24	7,632.20

* Refer note No. 2

NOTES:

- DIL Limited ('the Company') is in the business of property development, motion film production and distribution and in treasury operation. The Company also has strategic investments in subsidiaries / joint venture which are engaged in contract research services, manufacturing of bulk drugs and wheel chairs. The above unaudited financial results are presented on a stand alone basis as well as on a consolidated basis so as to include the operations of the Company's subsidiaries and joint venture (Group).
- During the current quarter, the Company and its subsidiaries changed the method of depreciation from written down value to straight line method. As a result of the change, the Company has written back depreciation of Rs. 158.12 Lakhs and Rs. 337.10 Lakhs in the standalone and consolidated financial results for the current quarter respectively. Further, the depreciation charge in the standalone and consolidated financial results for the current quarter is lower by Rs. 8.91 Lakhs and Rs. 28.97 Lakhs, respectively.
- During the current quarter, Fermenta Biotech Limited (FBL), a subsidiary of the Company has entered in to an agreement for transfer of the throat lozenges business along with the trademark "ASTRASEPT" and the related movable fixed assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary, G.I. Biotech Private Limited ('GI'). Further, FBL has also entered into a share transfer agreement with a party to transfer its entire share holding in GI in four instalments to be completed by 10th February, 2009 for a total consideration of US\$ 400,000. In accordance with the share transfer agreement, during the quarter, the Company sold 630 shares of GI and recorded profit on sale of shares of Rs. 10.46 lakhs.
- The expenses of the Company in stand alone results are stated net of recovery from subsidiaries.
- The Company has invested an aggregate of Rs. 188.51 Lakhs in VasKo Glider s.r.o. Czechoslovakia, a joint venture in the form of basic capital of Rs. 1.96 Lakhs and voluntary capital of Rs. 186.55 Lakhs. The joint venture is involved in manufacture of wheel chair based on Levitation Movement Technology, the patent for which has recently been registered by U.S. patent authorities. The Company believes that the said investment has long term potential on commercialisation. The Statutory Auditors of the Company are unable to express their opinion on the carrying value of this investment.
- Previous year's figures have been regrouped wherever necessary.
- There were no investor complaints pending at the quarter ended June 30, 2008. No complaints were received during the quarter ended June 30, 2008.
- The above unaudited quarterly results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on July 29, 2008.

MUMBAI
July 29, 2008

For DIL Limited



Krishna Datla
Managing Director

